Magdalena biosciences, a joint venture between jaguar health and filament health, to present february 10th at bio ceo & investor conference

Magdalena aiming to submit investigational new drug (ind) application in 2025 to the fda for a next-generation psychoactive prescription drug candidate for potential mental health indications such as adhd and schizophrenia, with 1-2 additional ind applications filed in late 2025/early 2026 san francisco, ca / access newswire / february 6, 2025 / jaguar health, inc. (nasdaq:jagx) today announced that dr. karen brunke, jaguar's evp of corporate and business development and acting ceo of magdalena biosciences, inc. (magdalena), the joint venture formed by jaguar and filament health corp. (otcqb:flhlf) (cboe ca:fh) (fse:7qs) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting in person on monday, february 10, 2025 at 2:30 pm eastern at the bio ceo & investor conference in new york city. "i very much look forward to providing an overview of magdalena at this conference and meeting with potential partners and investors at this event," dr. brunke said.
JAGX Ratings Summary
JAGX Quant Ranking